Analytical Data
-
Gene name
PEAK1
- Application
-
Alternative Names
FLJ21140; FLJ34483; KIAA2002; NKF3 kinase family member ; PEAK1; PEAK1_HUMAN; pseudopodium enriched atypical kinase; Pseudopodium-enriched atypical kinase 1; SGK269; Sugen kinase 269; Tyrosine-protein kinase SgK269
-
Species
Human
-
Source
E. coli
-
Tag
GST-tag at N-terminal
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9H792
-
Expression Region
1151-1250 aa
-
AA Sequence
TPPPLPKKMIIRANTEPISKDLQKSMESSLCVMANPTYDIDPNWDASSAGSSISYELKGLDIESYDSLERPLRKERPVPSAANSISSLTTLSIKDRFSNS
-
Molecular Weight
36.63 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PEAK1, or Pseudopodium-enriched atypical kinase 1, is a member of the Ser/Thr kinase family, primarily involved in regulating cytoskeletal dynamics and cellular signaling pathways. Its significance has been underscored in various biological processes, including cell migration, adhesion, and proliferation. Abnormal expression and activity of PEAK1 have been linked to multiple diseases, particularly cancer, where it is believed to contribute to tumor progression and metastasis. Recent studies have indicated that PEAK1 functions as a key mediator in the signaling pathways activated by extracellular stimuli, thereby influencing cellular responses to the microenvironment. The interest in PEAK1 as a therapeutic target has spurred efforts to produce recombinant PEAK1 protein, enabling detailed investigations into its structure, function, and interactions at the molecular level. By generating and characterizing this recombinant protein, researchers aim to elucidate the precise mechanisms by which PEAK1 influences cellular behavior and to explore its potential as a novel biomarker or therapeutic target in cancer and other diseases. The study of PEAK1 not only enhances our understanding of fundamental cellular processes but also opens new avenues for targeted therapies in oncology, making it a focal point in current biomedical research.
